|
|
|
|
| | | | USD | EUR | GBP | JPY | 83.30 | 89.11 | 103.69 | 0.54 |
| | | | AED | AUD | CHF | CAD | 17.54 | 49.53 | 64.49 | 50.06 |
| | | | HKD | SAR | SGD | ZAR | 8.28 | 17.22 | 47.46 | 4.57 |
|
|
|
|
|
|
|
|
|
|
|
Industry :
|
Pharmaceuticals & Drugs
|
|
|
|
|
|
|
|
|
|
52-Week-High (Rs.)
|
132.40
|
|
|
|
|
|
|
* BSE PRICES
|
|
|
|
|
Particulars | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Operational & Financial Ratios | | | | | | Earnings Per Share (Rs) | 0.80 | 12.42 | 17.67 | 5.21 | -5.07 | CEPS(Rs) | 7.74 | 18.89 | 23.47 | 10.41 | -0.60 | DPS(Rs) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | Book NAV/Share(Rs) | 96.00 | 95.12 | 82.63 | 65.67 | 60.44 | Tax Rate(%) | 42.63 | 29.12 | 29.22 | -32.00 | -39.98 | Margin Ratios | | | | | | Core EBITDA Margin(%) | 6.86 | 10.88 | 15.08 | 7.57 | 3.74 | EBIT Margin(%) | 4.02 | 8.62 | 12.70 | 5.32 | 1.12 | Pre Tax Margin(%) | 0.59 | 6.15 | 10.27 | 2.00 | -2.22 | PAT Margin (%) | 0.34 | 4.36 | 7.27 | 2.64 | -3.10 | Cash Profit Margin (%) | 3.29 | 6.63 | 9.66 | 5.26 | -0.36 | Performance Ratios | | | | | | ROA(%) | 0.37 | 6.64 | 11.31 | 3.73 | -3.67 | ROE(%) | 0.84 | 13.97 | 23.83 | 8.27 | -8.05 | ROCE(%) | 6.56 | 18.34 | 28.01 | 10.66 | 1.76 | Asset Turnover(x) | 1.08 | 1.52 | 1.56 | 1.42 | 1.18 | Sales/Fixed Asset(x) | 1.60 | 2.15 | 2.09 | 1.86 | 1.61 | Working Capital/Sales(x) | 9.03 | 8.21 | 15.49 | 32.26 | 18.19 | Efficiency Ratios | | | | | | Fixed Capital/Sales(x) | 0.62 | 0.47 | 0.48 | 0.54 | 0.62 | Receivable days | 45.61 | 40.78 | 44.73 | 33.58 | 44.31 | Inventory Days | 124.81 | 71.08 | 58.56 | 80.60 | 94.20 | Payable days | 110.40 | 58.29 | 72.42 | 83.15 | 83.21 | Valuation Parameters | | | | | | PER(x) | 121.95 | 8.28 | 5.62 | 5.82 | 0.00 | PCE(x) | 12.63 | 5.44 | 4.24 | 2.92 | -92.64 | Price/Book(x) | 1.02 | 1.08 | 1.20 | 0.46 | 0.91 | Yield(%) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | EV/Net Sales(x) | 0.61 | 0.53 | 0.57 | 0.34 | 0.65 | EV/Core EBITDA(x) | 8.74 | 4.88 | 3.80 | 3.88 | 14.88 | EV/EBIT(x) | 15.15 | 6.16 | 4.52 | 5.79 | 51.13 | EV/CE(x) | 0.63 | 0.73 | 0.84 | 0.42 | 0.70 | M Cap / Sales | 0.42 | 0.36 | 0.41 | 0.17 | 0.38 | Growth Ratio | | | | | | Net Sales Growth(%) | -17.47 | 17.25 | 36.25 | 24.07 | -18.54 | Core EBITDA Growth(%) | -47.19 | -15.30 | 133.25 | 148.80 | -79.04 | EBIT Growth(%) | -61.52 | -20.37 | 193.25 | 472.52 | -92.93 | PAT Growth(%) | -93.54 | -29.72 | 238.94 | 202.76 | -140.38 | EPS Growth(%) | -93.54 | -29.72 | 238.94 | 202.76 | -140.38 | Financial Stability Ratios | | | | | | Total Debt/Equity(x) | 0.49 | 0.52 | 0.49 | 0.48 | 0.66 | Current Ratio(x) | 1.25 | 1.42 | 1.23 | 1.09 | 1.16 | Quick Ratio(x) | 0.42 | 0.52 | 0.69 | 0.50 | 0.35 | Interest Cover(x) | 1.17 | 3.48 | 5.24 | 1.60 | 0.34 | Total Debt/Mcap(x) | 0.48 | 0.48 | 0.41 | 1.04 | 0.72 |
|
|
|
|
|
|